No specific antiviral; management is supportive, centered on careful fluid management and monitoring for plasma leakage/shock.
Dengue without warning signs (outpatient management):
Adequate oral fluid intake (oral rehydration solution, fruit juice, avoid excessive plain water)
Paracetamol for fever/pain — strictly avoid NSAIDs (ibuprofen, aspirin, diclofenac) and other salicylates — bleeding risk and Reye's syndrome
Daily review: temperature, fluid intake/output, warning signs, FBC (hematocrit, platelets)
Educate on warning signs requiring immediate return
Dengue with warning signs (admit for monitoring):
IV isotonic crystalloids (normal saline or Ringer's lactate) starting at 5–7mL/kg/hour, titrate based on clinical response, hematocrit, urine output
Monitor vitals, urine output, hematocrit every 4–6 hours during critical phase
Reduce IV rate as patient stabilizes/enters recovery phase (risk of fluid overload once leakage resolves — this is a common cause of iatrogenic harm if fluids not tapered)
Severe dengue/dengue shock syndrome (ICU-level care):
Aggressive fluid resuscitation: IV crystalloid bolus 10–20mL/kg over 1 hour, reassess; consider colloids (e.g., dextran) if repeated boluses fail
Blood transfusion if significant hemorrhage (whole blood or packed cells); platelet transfusion NOT routinely indicated for thrombocytopenia alone without active bleeding — even very low counts (<10,000-20,000) are managed expectantly unless bleeding present
Correct hypoglycemia, electrolyte imbalances, metabolic acidosis
Manage organ-specific complications (hepatic failure, encephalopathy, myocarditis) supportively
Avoid IM injections and unnecessary invasive procedures (bleeding risk)
Discharge criteria: afebrile ≥24 hours without antipyretics, improved appetite, stable hematocrit, platelet count rising (>50,000), no respiratory distress, adequate urine output.
Prevention: vector control (eliminate breeding sites, insecticide-treated nets, repellents), dengue vaccine (CYD-TDV/Dengvaxia — only for seropositive individuals due to ADE risk in seronegative recipients; TAK-003/Qdenga — broader use profile, check local guidelines).